10% Owner Daniel Schneeberger Buys Additional $711K in Rallybio Stock
RLYB has more than doubled off its 52-week low of $2.16.
Summary
Daniel Schneeberger, a 10% owner of Rallybio Corp, made additional open market purchases totaling over $711,000, increasing his stake in the company following a recent merger termination.
Key Events · Ownership and Investor Activity · RLYB
-
Significant Insider Purchase
Daniel Schneeberger, a 10% owner, acquired 50,800 shares of Rallybio common stock in open market transactions totaling $711,055. These purchases occurred between May 11 and May 12, 2026, at prices ranging from $13.83 to $14.00 per share.
-
Continued Accumulation
This filing marks a continuation of significant buying by Schneeberger, following a previous Form 4 on May 7, 2026, which reported over $2.18 million in purchases. His total open market buys in the past week now approach $2.9 million.
-
Post-Merger Termination Context
These insider purchases occur shortly after Rallybio Corp announced the termination of its reverse merger agreement with Candid Therapeutics on May 4, 2026. The termination included a $50 million fee, which significantly bolstered Rallybio's cash reserves and extended its operational runway.
Analysis · RLYB · Life Sciences
This continued substantial open market buying by a 10% owner, Daniel Schneeberger, signals strong conviction in Rallybio's prospects. These purchases follow the recent termination of a reverse merger agreement, which resulted in a $50 million termination fee, significantly boosting the company's cash reserves. The repeated insider investment suggests a positive outlook on the company's standalone strategy and financial health.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $14.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.9M. The 52-week trading range was $2.16 to $15.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.